OBJECTIVE: To observe the effect of long-term application of Shengmai Capsule (SMC) on recovery of patients after myocardial infarction. METHODS: A total of 120 myocardial infarction patients were: assigned into two groups. Changes of angina pectoris, electrocardiogram (ECG), living capacity and heart function in patients were observed after 6-month treatment. RESULTS: The total effective rate in alleviating angina: pectoris was 90.0% and that in improving ECG figure was 93.3% in the treatment group, both were significantly higher than those in the control group, 73.4% and 70.0% respectively (P<0.05). The Karnofsky Performance Status scores of heart function were increased and the Activity of Daily Living scores in living capacity decreased in both groups, but the improvements were better in the treatment group (P<0.01 and P<0.05). The parameters of cardiac function, including cardiac output, stroke volume, cardiac index and ejection fraction, were increased in both groups, but the increments in the treatment group were more significant (P<0.01 or P<0.05). CONCLUSION: Long-term application of SMC could effectively prevent and treat angina pectoris, improve the living capacity and accelerate the recovery of heart function in patients after myocardial infarction.
RCT Entities:
OBJECTIVE: To observe the effect of long-term application of Shengmai Capsule (SMC) on recovery of patients after myocardial infarction. METHODS: A total of 120 myocardial infarctionpatients were: assigned into two groups. Changes of angina pectoris, electrocardiogram (ECG), living capacity and heart function in patients were observed after 6-month treatment. RESULTS: The total effective rate in alleviating angina: pectoris was 90.0% and that in improving ECG figure was 93.3% in the treatment group, both were significantly higher than those in the control group, 73.4% and 70.0% respectively (P<0.05). The Karnofsky Performance Status scores of heart function were increased and the Activity of Daily Living scores in living capacity decreased in both groups, but the improvements were better in the treatment group (P<0.01 and P<0.05). The parameters of cardiac function, including cardiac output, stroke volume, cardiac index and ejection fraction, were increased in both groups, but the increments in the treatment group were more significant (P<0.01 or P<0.05). CONCLUSION: Long-term application of SMC could effectively prevent and treat angina pectoris, improve the living capacity and accelerate the recovery of heart function in patients after myocardial infarction.
Authors: D Brezinski; P H Stone; J E Muller; G H Tofler; V Davis; C Parker; L H Hartley; E Braunwald Journal: Am Heart J Date: 1991-05 Impact factor: 4.749
Authors: Ali Shafiq; Natalie Jayaram; Kensey L Gosch; John A Spertus; Donna M Buchanan; Carole Decker; Mikhail Kosiborod; Suzanne V Arnold Journal: Clin Cardiol Date: 2016-05-31 Impact factor: 2.882